Nyxoah (NYXH NASDAQ) stock market data APIs
$5.6875
0.12(2.1%)
as of October 21, 2025
Try our APIs with
free plan!
Nyxoah Financial Data Overview
Price chart is built with
Anychart
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Prev. Close
5.6875
Open
5.8094
High
5.9062
Low
5.678
52 wk Range
4.345-11.87
Market Cap
221 M
Shares Outstanding
37 545 K
Revenue
4 933 K
EPS
-0.6432
Beta
0.578
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nyxoah data using free add-ons & libraries
Get Nyxoah Fundamental Data
Nyxoah Fundamental data includes:
- Net Revenue: 4 933 K
- EBITDA: -72 890 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-18
- EPS/Forecast: -0.6459
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nyxoah News
New
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
Nyxoah NYXH has begun its U.S. commercial rollout of the Genio system, following FDA approval for its leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA). The first comme...
Nyxoah Launches Genio System In U.S. With First Commercial Implants For Sleep Apnea
(RTTNews) - Nyxoah SA (NYXH), a medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA), announced the successful implantation of its Genio system in the fir...
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverag...
Nyxoah Annonce les Premiers Patients Commerciaux Aux États-Unis Implantés avec le Système Genio®
Nyxoah Annonce les Premiers Patients Commerciaux Aux États-Unis Implantés avec le Système Genio® Le lancement commercial initial témoigne d'une forte demande de la part des médecins, de préaut...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
